Essai clinique NCT06561386 · Non-small Cell Lung Cancer

Essai clinique NCT06561386 (phase III) est «en recrutement» sur ClinicalTrials.gov.

Pathologie: Non-small Cell Lung Cancer · Interventions enregistrées: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin · Dates enregistrées (source): 2024-10-07, 2030-07-30, 2024-08-20, 2026-10-23.

Résumé de l’étude (source : ClinicalTrials.gov, texte original en anglais):

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Source: https://clinicaltrials.gov/study/NCT06561386